{
  "docId": "019de075-a749-75ad-9c96-b2ef130e2f41",
  "docSlug": "810e8355c3b124b062a449d6b3848ba9",
  "documentTitle": "Immix Biopharma | Investor Presentation Deck | 49 slides",
  "authorId": "immix-biopharma",
  "authorName": "Immix Biopharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 8,
  "pageCount": 49,
  "prevPage": 7,
  "nextPage": 9,
  "slideType": "solution",
  "function": "present_solution",
  "density": "balanced",
  "nDataPoints": 3,
  "notes": "Includes a cartoon liver character, likely representing the target organ or safety profile.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-a749-75ad-9c96-b2ef130e2f41/8",
  "deckHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41",
  "deckJsonHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41.json",
  "deckAnchorHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41#slide-8",
  "components": [
    {
      "bbox": {
        "h": 0.7,
        "w": 0.85,
        "x": 0.08,
        "y": 0.2
      },
      "kind": "diagram",
      "text": "Hub-and-spoke diagram showing No Neurotoxicity as the central benefit with four supporting clinical outcomes.",
      "attrs": null,
      "subkind": "hub-spoke",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1a34096f-2c8a-4e03-82e9-959f154a3c92",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.2,
        "x": 0.4,
        "y": 0.7
      },
      "kind": "image",
      "text": "Cartoon liver character",
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e780fcdd-6304-4bb6-b822-6a1728d73212",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.55,
        "x": 0.02,
        "y": 0.05
      },
      "kind": "title",
      "text": "NXC-201 Can Resolve Pain Points with No Neurotoxicity",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e7f34c44-1303-4cb8-bfca-9c91c8809ad7",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Audience Definition",
      "slug": "audience-definition",
      "agent": "Storyteller",
      "layer": "slide",
      "matchId": "1e4497e0-28ba-48f7-bdc5-f3db869bd957",
      "evidence": "The slide presents a solution with a central benefit and supporting clinical outcomes, indicating that the target audience is likely medical professionals or patients familiar with clinical trials and treatment options.",
      "confidence": 0.7
    },
    {
      "name": "Problem-Agitate-Solve (PAS)",
      "slug": "problem-agitate-solve-pas",
      "agent": "Storyteller",
      "layer": "slide",
      "matchId": "ff33fee5-2b2f-47a1-90bd-900e48918007",
      "evidence": "The slide mentions 'pain points' and presents NXC-201 as a solution, which is a common structure for Problem-Agitate-Solve (PAS) storytelling.",
      "confidence": 0.6
    }
  ],
  "frameworks": [
    {
      "name": "hub-spoke",
      "slug": null,
      "matchId": "6248df05-35c8-474b-866e-d23edb30d086",
      "evidence": "Central node connected to four peripheral nodes",
      "confidence": 1
    }
  ],
  "arcBeats": [
    {
      "to": 21,
      "from": 8,
      "beatId": "a874b208-4408-43df-9863-8c8c163ed01d",
      "arcName": "The Consultant's Gambit",
      "arcSlug": "consultants-gambit",
      "beatName": "Evidence & Proof",
      "beatSlug": "consultants-gambit-evidence-proof",
      "evidence": "Presentation of clinical data and competitive analysis for NXC-201",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [
    {
      "to": 21,
      "from": 7,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "6ea19383-9ed5-41d1-ac2b-d7d037efe2d8",
      "evidence": "Discussion of neurotoxicity associated with existing BCMA CAR-T therapies",
      "position": 0,
      "objective": "Highlighting the need for improved therapies",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}